Study of Card14 gene Polymorphism and Its Effect on Methotrexate Treatment in Egyptian Patients with Moderate to Severe Psoriasis and Psoriatic Arthritis

What this Trial Is About

Psoriasis is a chronic inflammatory skin disease affecting 1-3% of people worldwide and is caused by immune system interactions involving genes and environmental factors. Psoriatic arthritis PsA is an autoimmune condition linked to psoriasis that causes joint pain, stiffness, and swelling with varying severity. This research investigates the relationship between a specific gene variation Card14 gene rs34367357 and the response to methotrexate treatment in Egyptian patients with psoriasis and psoriatic arthritis. Participants receive either methotrexate, a drug commonly used for moderate to severe psoriasis and psoriatic arthritis, or a placebo. Methotrexates role is to reduce inflammation and skin symptoms, with the study evaluating how the Card14 gene polymorphism affects treatment response. The study groups include patients with psoriasis, those with psoriatic arthritis, and a healthy control group, with treatment effects assessed over a three-month period. During the study, participants undergo clinical assessments of their skin and joint symptoms, including severity scoring. Researchers monitor treatment response and any side effects throughout the three months. The study uses randomized allocation without blinding and involves regular evaluations to measure changes in psoriasis severity and arthritis symptoms, ensuring participant safety and treatment adherence over the trial period.

Card14gene (rs34367357 ) Polymorphism in Egyptian Psoriatic and Psoriatic Arthritis Patient